Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

  • Dogan, Erkan (Department of Medical Oncology, Regional Training and Research Hospital) ;
  • Yalcin, Suayib (Department of Medical Oncology, Hacettepe University Institute of Oncology) ;
  • Koca, Dogan (Department of Medical Oncology, Regional Training and Research Hospital) ;
  • Olmez, Aydemir (Department of General Surgery, Van Yuzuncu Yil University)
  • Published : 2012.06.30


Background: Hepatocellular carcinoma (HCC), the main malignant tumor of the liver, is very common and highly lethal. The aim of this study was to determine its clinicopathologic characteristics and risk factors in Turkey. Materials and methods: In this study, patients who were diagnosed as suffering from HCC in the period between August 2004 and December 2011 were evaluated retrospectively. Results: A total of 98 patients were included, with a median age 61 (range: 16 to 82). Seventy nine (80.6%) were male 59 (60.2%) were infected with hepatitis B virus (HBV) and 15 (15.3%) with HCV, another 15 (15.3%) being alcohol abusers. Seventy two (73.5%) were at advanced stage and 54 (55.1%) had elevated serum alpha-fetoprotein (AFP). Surgery, chemoembolization, systemic chemotherapy and application of the tyrosine kinase inhibitor sorafenib were the major treatment options. Conclusions: According to our findings HCC is mostly diagnosed in advanced stage and age, being five times more common in males than females. Main risk factors of HCC are HBV infection, HCV infection and alcohol abuse. Elevation in AFP may facilitate early diagnosis of HCC in high risk groups.


  1. Alacacioglu A, Somali I, Simsek I, et al (2008). Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol, 38, 683-8.
  2. Beasley RP, Hwang LY, Lin CC, et al (1981). Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet, 2, 1129-33.
  3. Bosch FX, Ribes J, Diaz M, Cleries R, (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, 5-16.
  4. Bugianesi E (2007). Non-alcoholic steatohepatitis and cancer. Clin Liver Dis, 11, 191-207.
  5. Calvet X, Bruix J, Bru C, et al (1990). Natural history of hepatocellular carcinoma in Spain. Five years' experience in 249 cases. J Hepatol, 10, 311-7.
  6. Chan KM, Chou HS, Wu TJ, et al (2011). Characterization of hepatocellular carcinoma recurrence after liver transplantation: perioperative prognostic factors, patterns, and outcome. A J Surg, 34, 128-34.
  7. Daniele B, Bencivenga A, Megna AS, et al (2004). Alphafetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology, 127, 108-12.
  8. DeVita VT, Lawrence TS, Rosenberg SA (2008). CANCER Principles & Practice of Oncology. Philadelphia, USA: Lippincott Wiilıams & Wilkins, ?, 1129.
  9. DeVita VT, Lawrence TS, Rosenberg SA (2008). CANCER Principles & Practice of Oncology. Philadelphia, USA: Lippincott Wiilıams & Wilkins, ?, 1130-3.
  10. Degos F, Christidis C, Ganne-Carrie N, et al (2000). Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut, 47, 131-6.
  11. Di Bisceglie AM (1997). Hepatitis C and hepatocellular carcinoma. Hepatology, 26, 34-8.
  12. Edge SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th editionof the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4.
  13. El-Serag HB, Mason AC (1999). Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med, 340, 745-50.
  14. Fattovich G, Brollo L, Giustina G, et al (1991). Natural history and prognostic factors for chronic hepatitis type B. Gut, 32, 294-8.
  15. Fattovich G, Giustina G, Degos F, et al ( 1997). Morbidity and mortality in ompensated cirrhosis type C: a Retrospective follow-up study of 384patients. Gastroenterology, 112, 463-72.
  16. Fattovich G, Llovet JM (2006). Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing. J Hepatol, 44, 1013-6.
  17. Giannelli G, Antonaci S, (2006). New frontiers in biomarkers for hepatocellular carcinoma. Dig Liver Dis, 38, 854-9.
  18. Hajiani E, Masjedizadeh R, Hashemi J, et al (2005). Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J, 26, 974-7.
  19. Hassan MM, Hwang LY, Hatten CJ, et al (2002). Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 36, 1206-13.
  20. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
  21. Kamangar F, Dores GM, Anderson WF, (2006). Patterns of cancer incidence, mortality,and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50.
  22. Koike K, Tsutsumi T, Fujie H, et al (2002) . Molecular mechanism of viral hepatocarcinogenesis. Oncology, 62, 29-37.
  23. Law MG, Roberts SK, Dore GJ, Kaldor JM (2000). Primary hepatocellular carcinoma in Australia, 1978-1997: increasing incidence and mortality. Med J Aust, 173, 403-5.
  24. Lee FI (1966). Cirrhosis and hepatoma in alcoholics. Gut, 7, 77-85.
  25. Liaw YF, Sung JJ, Chow WC (2004). Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351, 1521-31.
  26. Llovet JM, Brú C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38.
  27. Lok AS (2004). Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology, 127, 303-9.
  28. Ma C, Chi M, Su H, et al (2012). Evaluation of the Clinical Features of Hepatocellular Carcinoma following Hepatectomy for Different Stages of Hepatocellular Carcinoma. Hepatogastroenterology, 59, ?-?.
  29. Manno M, Camma C, Schepis F, et al (2004). Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology, 127, 756-63.
  30. Marrero JA, Lok AS (2004). Newer markers for hepatocellular carcinoma. Gastroenterology, 127, 113-9.
  31. Moriyama M, Matsumura H, Aoki H, et al (2003). Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. Intervirology, 46, 296-307.
  32. Nagasue N, Ogawa Y, Yukaya H, et al (1985). Serum levels of estrogens and testosterone in cirrhotic men with and without hepatocellular carcinoma. Gastroenterology, 88, 768-72.
  33. Okuda K, Ohtsuki T, ONE AUTHOR, et al (1985). Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer, 56, 918-28.<918::AID-CNCR2820560437>3.0.CO;2-E
  34. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.
  35. Prates MD, Torres FO (1965). A cancer survey in Lourenço Marques, Portuguese East Africa. J Natl Cancer Inst, 35, 729-57.
  36. Remontet L, Esteve J, Bouvier AM, et al (2003). Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique, 51, 3-30.
  37. Schaefer S (2005). Hepatitis B virus: significance of genotypes. J Viral Hepat, 12, 111-24.
  38. Schoniger-Hekele M, Muller C, Kutilek M, et al (2000). Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation. Eur J Gastroenterol Hepatol, 12, 941-8.
  39. Simonetti J, Bulkow L, McMahon BJ, et al (2010). Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology, 51, 1531-7.
  40. Taylor-Robinson SD, Foster GR, Arora S, et al (1997). Increase in primary liver cancer in the UK, 1979-94. Lancet, 350, 1142-3.
  41. The CLIP investigators (1998). A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology, 28, 751-5.
  42. Tsujita E, Yamashita Y, Takeishi K, et al (2012). Poor prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma in the modern era. Am Surg, 78, 419-25.
  43. Trevisani F, De NS, Rapaccini G, et al (2002). Semi-annual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol, 97, 734-44.
  44. Tsukuma H, Hiyama T, Tanaka S, et al (1993). Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med, 328, 1797-801.
  45. Ueno Y, Nagata S, Tsutsumi T, et al (1996). Detection of microcystins, a blue-green algal hepatotoxin, in drinking water sampled in Haimen and Fusui, endemic areas of primary liver cancer in China, by highly sensitive immunoassay. Carcinogenesis, 17, 1317-21.
  46. Velazquez RF, Rodriguez M, Navascues CA, et al (2003). Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology, 37, 520-7.
  47. Yu SZ (1995). Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol, 10, 674-82.
  48. Xu J, Liu C, Zhou L, et al (2012). Distinctions Between clinicopathological factors and prognosis of alphafetoprotein negative and positive hepatocelluar carcinoma patients. Asian Pac J Cancer Prev, 13, 559-62.

Cited by

  1. Association of Type II Diabetes Mellitus with Hepatocellular Carcinoma Occurrence - a Case Control Study from Kathmandu Valley vol.13, pp.10, 2012,
  2. Multicenter Epidemiologic Study on Hepatocellular Carcinoma in Turkey vol.15, pp.6, 2014,
  3. Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience vol.15, pp.9, 2014,
  4. Prevalence of K-Ras mutations in hepatocellular carcinoma: A Turkish Oncology Group pilot study vol.3, pp.6, 2015,
  5. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review vol.16, pp.3, 2016,